Abstract:Pheochromocytoma/paraganglioma (PPGL) is an endocrine-related tumor associated with exces-sive catecholamine release and has limited treatment options once metastasis occurs. Although recent phase 2 clinical trials of immune checkpoint inhibitors in the treatment of PPGL have preliminarily shown promising results, the fundamentals of immunotherapy for PPGL have not yet been established. In the early research, using bulk RNA sequencing of tumor samples from 7 PPGL patients, we found that PPGL tumor tissues exhibited high PD-L1 mRNA expression compared with adjacent normal adrenal medulla tissues, and this was related to T-cell exhaustion biomarkers. To further validate the association, in this study (n 1/4 60), we first stratified all PPGL samples ac-cording to PD-L1 expression as determined by immunohistochemical staining, and then subjected 23 fresh PPGL tumor samples from the cohort to a quantitative polymerase chain reaction (n 1/4 16), flow cytometry (n 1/4 7), and multiplex-immunofluorescence staining. Subsequently, we evaluated the pathological manifestations of all 60 PPGL tumor samples and analyzed the correlation among PD-L1 expression, adverse pathological behavior, various clinicopathological data, and genotypes in PPGL. The results showed that PD-L1-positive expression correlated with the exhaustion of tumor-infiltrating T cells, preoperative abnormal elevation of plasma norepinephrine, high Ki67 index, and adverse pathological behavior in PPGL but not with genetic mutation or metastatic disease, possibly due to the limitation of the small number of patients with metastatic disease (n 1/4 4) in the study cohort. In conclusion, our findings reveal that PD-L1 expression is associated with T-cell exhaustion and adverse pathological behavior in PPGL. These results are expected to provide a new theoretical basis and clinical guidance for the treatment of PPGL.& COPY; 2023 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Gene expression profiles of phaeochromocytomas with ERBB2 overexpression reveal a new molecular mechanism tumourigenicity.

ERBB-2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas.

Overexpression Of Erbb-2 Was More Frequently Detected In Malignant Than Benign Pheochromocytomas By Multiplex Ligation-Dependent Probe Amplification And Immunohistochemistry

The expression and significance of ERBB2、p-ERK、p-AKT、p-JNK in pheochromocytomas

Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas

Bioinformatic Analysis of Differentially Expressed Genes As Prognostic Markers in Pheochromocytoma and Paraganglioma Tumors.

Clinical and molecular immune characterization of ERBB2 in glioma

Recent progress in molecular classification of phaeochromocytoma and paraganglioma

P3-015: Clinicopathologic Features and Epidermal Growth Factor Receptor Mutations Associated with Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer

The Expression of the EGF Receptor Family and Their Ligands in Human Medulloblastomas

Molecular and Clinicopathological Characteristics of ERBB2 Gene Fusions in 32,131 Chinese Patients with Solid Tumors.

Expression of phospho-MAPK in non-small cell cancer and its clinicopathological significance

Clinical Significance and Prognostic Value of Extracellular Signal-Regulated Kinases in Epithelial Ovarian Cancer

The gene expression profiling of sporadic pheochromocytoma and novel full-length cDNAs cloning

PD-L1 Expression is Linked to Tumor-Infiltrating T-Cell Exhaustion and Adverse Pathological Behavior in Pheochromocytoma/Paraganglioma.

Overexpression of G Protein-Coupled Receptors in Cancer Cells: Involvement in Tumor Progression.

Genes Dysregulated To Different Extent Or Oppositely In Estrogen Receptor-Positive And Estrogen Receptor-Negative Breast Cancers

Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions

Transcriptome-guided resolution of tumor microenvironment interactions in pheochromocytoma and paraganglioma subtypes

Significance of genes encoding peptide processing factors In differential diagnosis of benign and malignant pheochromocytomas

Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas